Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) – Pipeline Review, H2 2016’, provides in depth analysis on Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) targeted pipeline therapeutics.

The report provides comprehensive information on the Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN)

The report reviews Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) targeted therapeutics and enlists all their major and minor projects

The report assesses Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Phylogica Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 5

Global Markets Direct Report Coverage 5

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) Overview 6

Therapeutics Development 7

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Products under Development by Stage of Development 7

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Products under Development by Therapy Area 8

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Products under Development by Indication 9

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Pipeline Products Glance 10

Early Stage Products 10

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Products under Development by Companies 11

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Products under Development by Universities/Institutes 13

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Therapeutics Assessment 15

Assessment by Monotherapy/Combination Products 15

Assessment by Mechanism of Action 16

Assessment by Molecule Type 17

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Companies Involved in Therapeutics Development 18

Phylogica Ltd 18

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Drug Profiles 19

Drug to Inhibit C-Jun for Endometriosis - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

PYC-35 - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

PYC-36 - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

PYC-38 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

PYC-98 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Dormant Projects 24

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Discontinued Products 25

Appendix 26

Methodology 26

Coverage 26

Secondary Research 26

Primary Research 26

Expert Panel Validation 26

Contact Us 26

Disclaimer 27

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Action, H2 2016 16

Number of Products by Stage and Molecule Type, H2 2016 17

Pipeline by Phylogica Ltd, H2 2016 18

Dormant Projects, H2 2016 24

Discontinued Products, H2 2016 25

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Actions, H2 2016 16

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared